who medicines strategy - libdoc.who.int - World Health Organization

who medicines strategy - libdoc.who.int - World Health Organization who medicines strategy - libdoc.who.int - World Health Organization

steinergraphics.com
from steinergraphics.com More from this publisher
10.07.2015 Views

WHO MEDICINES STRATEGY 2004-2007 | 100EO 6.3Good practices in medicineregulation and quality assurancesystems to ensure that qualityis maintained in clinical trials,production, supply and distribution,and post-marketing surveillanceRationaleEssential tools (standards, norms, guidelines)and guidance for good regulatory and qualityassurance practices are widely available,but need to be constantly updated. Somegood practice guidelines, such as GMP andGood Clinical Practice (GCP) guidelines, arenormative documents. Others, like GoodRegulatory Practices, may be of more generalnature and oriented to improving the overallperformance of medicines regulatory agencies.Proper implementation of these regulatory andquality assurance tools according to locallyestablished standard operating procedures isessential as a quality management step for properimplementation of regulation, and to ensurethat the medicines used are safe, effective, andof good quality. The success of regulation isdependent not only on the regulators but alsoon the full compliance of those being regulated(manufacturers and distributors).ProgressAdditional guidelines and tools have beendeveloped, such as new GMP training modulesfor validation, water, heating, ventilation, andair conditioning systems. An external qualityassurance assessment scheme for national andregional quality control laboratories has beencontinued in all six WHO regions, involving 36laboratories. In addition, WHO has developed atool for reviewing national medicine regulatorycapacity, including implementation of GMPguidelines. The review is designed to help bothWHO and the concerned national authoritiesto identify priority areas for capacity building,technical advice, and support. This collaborativework has enabled assessments to be carriedout in a number of countries in order to identifyweaknesses in national regulatory authoritiesand action needed to strengthen capacity.The experience accumulated through thiscollaborative work has helped further refine thedata collection tools and the methodology of thereviews.

COMPONENTS OF THE STRATEGY | 101ChallengesThree types of common imbalance have beenidentified in regulatory practice:> much more time is assigned to premarketingassessment than to post-marketingsurveillance> while product registration is considered amajor responsibility by all the drug regulatoryauthorities, the regulation of drug distributionchannels and information does not enjoy thesame level of attention> in many countries, GMP inspection receivesmore attention and resources than inspectionof distribution channels. 54Meeting the challenges 2004-2007Over the next four years WHO will:> promote implementation of good practice byproviding necessary guidelines, tools, andtechnical assistance> continue to help Member States to assessregulatory capacity and improve regulatoryperformance by capacity building> continue to pursue the external qualityassessment scheme for medicines controllaboratories in all six WHO regions.The quality of products in the market is at riskif regulators and those being regulated fail toapply and monitor principles of good practice inproduction, supply and distribution of medicines,and post-marketing surveillance.OUTCOME INDICATORS1999 2003 2007#REPORTING % TARGET#REPORTING % TARGETNo. of countries with basic quality assurance procedures 95/122 78% 80% 111/137 81% 85%

WHO MEDICINES STRATEGY 2004-2007 | 100EO 6.3Good practices in medicineregulation and quality assurancesystems to ensure that qualityis ma<strong>int</strong>ained in clinical trials,production, supply and distribution,and post-marketing surveillanceRationaleEssential tools (standards, norms, guidelines)and guidance for good regulatory and qualityassurance practices are widely available,but need to be constantly updated. Somegood practice guidelines, such as GMP andGood Clinical Practice (GCP) guidelines, arenormative documents. Others, like GoodRegulatory Practices, may be of more generalnature and oriented to improving the overallperformance of <strong>medicines</strong> regulatory agencies.Proper implementation of these regulatory andquality assurance tools according to locallyestablished standard operating procedures isessential as a quality management step for properimplementation of regulation, and to ensurethat the <strong>medicines</strong> used are safe, effective, andof good quality. The success of regulation isdependent not only on the regulators but alsoon the full compliance of those being regulated(manufacturers and distributors).ProgressAdditional guidelines and tools have beendeveloped, such as new GMP training modulesfor validation, water, heating, ventilation, andair conditioning systems. An external qualityassurance assessment scheme for national andregional quality control laboratories has beencontinued in all six WHO regions, involving 36laboratories. In addition, WHO has developed atool for reviewing national medicine regulatorycapacity, including implementation of GMPguidelines. The review is designed to help bothWHO and the concerned national authoritiesto identify priority areas for capacity building,technical advice, and support. This collaborativework has enabled assessments to be carriedout in a number of countries in order to identifyweaknesses in national regulatory authoritiesand action needed to strengthen capacity.The experience accumulated through thiscollaborative work has helped further refine thedata collection tools and the methodology of thereviews.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!